Shares of Bio-Techne Corp (NASDAQ:TECH) have received an average rating of “Buy” from the eight analysts that are covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $128.75.

A number of research analysts have weighed in on the stock. Zacks Investment Research upgraded shares of Bio-Techne Corp from a “hold” rating to a “buy” rating and set a $136.00 target price on the stock in a research note on Wednesday, October 11th. Deutsche Bank AG set a $132.00 price target on shares of Bio-Techne Corp and gave the company a “buy” rating in a research report on Wednesday, August 30th. BidaskClub raised shares of Bio-Techne Corp from a “hold” rating to a “buy” rating in a research report on Wednesday, August 23rd. Finally, Wells Fargo & Company initiated coverage on shares of Bio-Techne Corp in a research report on Thursday, July 13th. They issued a “market perform” rating on the stock.

In related news, Director Karen A. Holbrook sold 1,059 shares of the company’s stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $121.73, for a total transaction of $128,912.07. Following the sale, the director now owns 914 shares of the company’s stock, valued at approximately $111,261.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold a total of 1,359 shares of company stock worth $164,632 in the last ninety days. 3.40% of the stock is currently owned by insiders.

A number of institutional investors have recently bought and sold shares of the stock. BlackRock Inc. increased its holdings in Bio-Techne Corp by 1.7% during the 2nd quarter. BlackRock Inc. now owns 3,561,574 shares of the biotechnology company’s stock worth $418,485,000 after acquiring an additional 61,138 shares during the period. Vanguard Group Inc. increased its holdings in Bio-Techne Corp by 1.2% during the 2nd quarter. Vanguard Group Inc. now owns 3,042,458 shares of the biotechnology company’s stock worth $357,489,000 after acquiring an additional 36,768 shares during the period. Atlanta Capital Management Co. L L C increased its holdings in Bio-Techne Corp by 0.7% during the 2nd quarter. Atlanta Capital Management Co. L L C now owns 1,960,895 shares of the biotechnology company’s stock worth $230,405,000 after acquiring an additional 14,291 shares during the period. Janus Henderson Group PLC increased its holdings in Bio-Techne Corp by 334.3% during the 2nd quarter. Janus Henderson Group PLC now owns 1,188,108 shares of the biotechnology company’s stock worth $139,603,000 after acquiring an additional 914,554 shares during the period. Finally, State Street Corp increased its holdings in Bio-Techne Corp by 0.5% during the 2nd quarter. State Street Corp now owns 994,739 shares of the biotechnology company’s stock worth $116,891,000 after acquiring an additional 5,078 shares during the period. 98.40% of the stock is currently owned by institutional investors and hedge funds.

WARNING: This piece of content was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/10/16/analysts-set-bio-techne-corp-tech-target-price-at-126-33.html.

Bio-Techne Corp (TECH) traded up 0.73% on Wednesday, reaching $122.54. 122,355 shares of the company’s stock traded hands. The stock has a market cap of $4.58 billion, a price-to-earnings ratio of 60.36 and a beta of 0.76. The company’s 50 day moving average is $121.82 and its 200-day moving average is $114.44. Bio-Techne Corp has a 52-week low of $95.68 and a 52-week high of $125.40.

Bio-Techne Corp (NASDAQ:TECH) last released its earnings results on Tuesday, August 8th. The biotechnology company reported $1.09 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.99 by $0.10. The firm had revenue of $156.60 million for the quarter, compared to analysts’ expectations of $150.25 million. Bio-Techne Corp had a net margin of 12.93% and a return on equity of 14.19%. The company’s quarterly revenue was up 16.2% on a year-over-year basis. During the same period in the previous year, the company earned $0.92 earnings per share. Equities analysts expect that Bio-Techne Corp will post $3.99 EPS for the current year.

Bio-Techne Corp Company Profile

Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world.

Analyst Recommendations for Bio-Techne Corp (NASDAQ:TECH)

Receive News & Stock Ratings for Bio-Techne Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne Corp and related stocks with our FREE daily email newsletter.